ARDS (Acute Respiratory Distress Syndrome) is a severe, life-threatening medical condition characterized by widespread inflammation and fluid accumulation in the lungs. Every year, this condition kills more people than breast and prostate cancer combined. With no approved pharmacotherapy and caused by pneumonia, sepsis and trauma, this is a huge unmet medical need.
Exvastat has created the first stable formulation of imatinib, Impentri™, that can be delivered intravenously. This hugely extends its value as it can be used with patients unable to receive oral treatments due to coma. This aspect transforms our ability to prevent the tragic loss of human life due to ARDS.Read more
In 2008, a woman with life-threatening pulmonary oedema was treated in an Amsterdam hospital…
She was resistant to all the normal therapeutic options, and treated off-label with imatinib, a drug then thought promising for pulmonary hypertension…
The oedema disappeared within 24 hours, leading to the hypothesis that the same drug could be effective in similar conditions, like Acute Respiratory Distress Syndrome (ARDS).
This has now been confirmed in a Phase II proof-of-concept study.
Partner with us to save livesContact us
Impentri™ is a high impact product that is uniformly effective in a heterogeneous condition. The new treatment is based on the drug's ability to inhibit vascular leak, which drives the pulmonary oedema. It has proven effective in a number of human case reports as well as in vivo models.
ARDS currently lacks any approved pharmaceutical therapy, with treatment limited to supportive ventilatory care. As Impentri™ can significantly reduce the high mortality and incapacitating morbidities caused by ARDS, it will radically reduce the cost of care.Read more
Aug 06, 2021
Further investment and three new appointments announced
Exvastat Ltd (“Exvastat”) receives further investment from Cambridge Innovation Capital and announce expansion of the team with three key new appointmentsRead more
Jul 12, 2021
First Patients Enter Clinical Trial of Impentri for COVID-19 ARDS
The Impentri IMI2 consortium are pleased to announce the first patients have entered their clinical trial to investigate the safety and efficacy of intravenous imatinib mesilate (Impentri™) in subjects with Acute Respiratory Distress Syndrome induced by COVID-19Read more
Jun 21, 2021
CounterCOVID study shows imatinib significantly reduces mortality by 49% in patients with COVID-19
Results published on Friday 18th June by Exvastat’s collaborator in The Lancet Respiratory Medicine show that oral imatinib, currently used to treat cancers, reduces mortality by 49% in hospitalized COVID-19 patients. The results of the world-first trial, led by VUmc, Amsterdam, could signify another option in the management of COVID-19 to protect livesRead more